Sign In
Buy ALVR
$9.81
+0 (+0%)
At Close: Jun 17, 2025
AlloVir shedding 95% of its staff after discontinuing T cell therapy trial
06:20pm, Thursday, 04'th Jan 2024
AlloVir Inc. ALVR, +5.02%, a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff, following an announcement las
AlloVir's stock suffers record plunge toward a record low after trials on T cell therapy
02:31pm, Friday, 22'nd Dec 2023
Shares of AlloVir Inc. ALVR, -66.75% plummeted 66.6% toward their first-ever close below $1 on heavy volume in afternoon trading Friday, after the immunotherapy company decided to discontinue the Phas
Why AlloVir Stock Dropped Today
02:44pm, Thursday, 21'st Sep 2023
AlloVir stock fell today given concerns over potential selling pressure from a recent lock-up expiration. The lock-up agreement was related to a new share issuance in June 2023.
AlloVir to Present at Upcoming Investor Conferences
07:00am, Monday, 28'th Aug 2023
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will p
5 Stocks With Rising P/E to Bet on for Solid Gains
08:22am, Monday, 07'th Aug 2023
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Crocs (CROX), AlloVir (ALVR), Arcadia Biosciences (RKDA), The Duckhorn Portfolio (NAPA) and Genuine Par
5 Top-Ranked Stocks With Rising P/E Worth Investing In
09:12am, Friday, 21'st Jul 2023
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Planet Fitness (PLNT), AlloVir (ALVR), Entergy (ETR), The Duckhorn Portfolio (NAPA) and Genuine P
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
08:31am, Thursday, 13'th Jul 2023
In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc. NASDAQ: ALVR and Arcus Biosciences Inc. NYSE: RC
AlloVir: 'Takes One To Know One'
07:13pm, Monday, 10'th Jul 2023
Gilead has purchased $10.9 million in shares of Allovir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownership of the company. Allovir's lead product, posoleuc
AlloVir: Several Late-Stage Programs Make This Worth A Look
03:48am, Saturday, 01'st Jul 2023
Positive final results from the phase 2 study, using posoleucel for BK Virus, were presented at the American Transplant Congress 2023. Discussions with FDA and key opinion leaders to align on phase 3
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why
01:33pm, Tuesday, 27'th Jun 2023
AlloVir, Inc. (ALVR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Shares of AlloVir Plummeted This Week
01:56pm, Friday, 23'rd Jun 2023
AlloVir stock fell to a 52-week low on Thursday. The company's lead therapy has begun phase 3 trials to treat kidney transplant patients who had virus infections.
Why Is AlloVir (ALVR) Stock Down 23% Today?
08:47am, Thursday, 22'nd Jun 2023
AlloVir (NASDAQ: ALVR ) stock is falling hard on Thursday after the company announced the pricing of a public share offering. That offering has AlloVir selling 20 million shares of ALVR stock for $3.7
Why Shares of AlloVir Jumped This Week
11:04am, Friday, 09'th Jun 2023
AlloVir is a clinical-stage biotech that focuses on viral therapies. The company has only enough cash to fund operations into early 2024.
AlloVir to Present at the BofA Securities 2023 Health Care Conference
07:00am, Monday, 01'st May 2023
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will p
Wall Street Analysts Predict a 281.43% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
11:18am, Friday, 10'th Feb 2023
The consensus price target hints at a 281.4% upside potential for AlloVir, Inc. (ALVR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
